Advertisement
Articles
Advertisement

Focus on Funding 10/27/06

Fri, 10/27/2006 - 7:57am


GOVERNMENT FUNDING

NCI Creates Network of Clinical Proteomic Technology Centers
The National Cancer Institute (NCI), announced funding for a major component of its $104 million, five-year Clinical Proteomic Technologies Initiative for Cancer, establishing a network of five Clinical Proteomic Technology Assessment for Cancer teams at the Broad Institute of MIT and Harvard, Cambridge, Mass., University of California, San Francisco/Lawrence Berkeley National Laboratory, Vanderbilt University School of Medicine, Nashville, Tenn., Purdue University, West Lafayette, Ind., and Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Full Article

NIH Launches National Consortium to Transform Clinical Research
The National Institutes of Health launched a national consortium to transform how clinical and translational research is conducted, beginning with 12 academic health centers (AHCs) located throughout the nation. An additional 52 AHCs are receiving planning grants to help them prepare applications to join the consortium.
Full Article

UCSD Granted $52M to Lead Alzheimer's Disease Study
The National Institutes of Health announced that the Alzheimer’s Disease Cooperative Study at the University of California, San Diego (UCSD) School of Medicine will receive $52 million over six years to conduct several new clinical trials on Alzheimer’s disease.
Full Article

MacroGenics Receives $62M to Advance Infectious Disease Programs
MacroGenics Inc., Rockville, Md., was awarded a National Institutes of Health $50 million contract over five years to develop a monoclonal antibody to West Nile virus as well as two additional grants totaling close to $13 million to support two new infectious disease programs.
Full Article

Alnylam Awarded $23M to Develop RNAi Therapeutics
Alnylam Pharmaceuticals Inc., Cambridge, Mass., announced that the National Institute of Allergy and Infectious Diseases has awarded the company a $23 million, four-year contract to advance the development of a broad spectrum RNAi anti-viral therapeutic against hemorrhagic fever virus, including the Ebola virus.
Full Article

GA Tech/Emory/MCG Partner on $10M NIH Nanomedicine Center
The National Institutes of Health (NIH) has awarded Georgia Institute of Technology, Atlanta, Emory University, and the Medical College of Georgia (MCG) a grant to partner on a Nanomedicine Development Center that will focus on DNA damage repair.
Full Article

Juvaris Awarded SBIR Grant for Leukemia Vaccine Development
Juvaris BioTherapeutics Inc., Pleasanton, Calif., was awarded a one-year, phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute in collaboration Penn State College of Medicine to develop a therapeutic vaccine approach to treat acute myelogenous leukemia.
Full Article

Lexicon Genetics Awarded Funding from DARPA
Lexicon Genetics Inc., The Woodlands, Texas, was awarded funding from the US Defense Advanced Research Projects Agency (DARPA) to identify targets in the development of drugs to enhance sleep benefits and offset problems associated with sleep deprivation.
Full Article

PRIVATE FUNDING

Athenagen Raises $50M in Series B Financing
Athenagen Inc., South San Francisco, Calif., raised $50 million through a Series B financing, which will be used to advance development of the company's lead programs targeting Alzheimer's disease, age-related macular degeneration, and cognition enhancement.
Full Article

Morphotek Raises $40M to Advance Antibody Pipeline
Morphotek Inc., Exton, Pa., closed on a $40 million Series D financing, which will be used primarily to further clinical development of its lead therapeutic antibodies, MORAb-003 and MORAb- 009, and to advance its pipeline of preclinical antibodies for the treatment of oncology, inflammatory, and infectious diseases.
Full Article

Xencor Completes $45M Financing
Xencor, Monrovia, Calif., raised $45 million in a private financing, which will be used to advance the clinical development of two biologic drug compounds, a first-in-class protein therapeutic and a novel antibody drug candidate.
Full Article

GRANTS AVAILABLE

Revolutionary Genome Sequencing Technologies: The $1,000 Genome
Agency: National Human Genome Research Institute
Estimated Funding: $1,500,000
Due Date for Applications: Nov. 25, 2006
Description: The National Human Genome Research Institute solicits grant applications to develop novel technologies that will enable extremely low-cost DNA sequencing, so that a mammalian-sized genome could be sequenced for approximately $1,000.
Full Article

2007 NIH Director's Pioneer Award Program
Agency: National Institutes of Health (NIH)
Estimated Funding: $500,000
Due Date for Applications: Jan. 17, 2007
Description: The NIH Director’s Pioneer Award Program, is a High-Risk Research initiative of Research Teams of the Future to describe highly innovative approaches that have the potential to produce an unusually high impact.
Full Article

Near-Term Technology Development for Genome Sequencing
Agency: National Human Genome Research Institute
Estimated Funding: N/A
Due Date for Applications: Nov. 25, 2006
Description: This funding opportunity seeks grant applications to develop novel technologies that will substantially reduce the cost of genomic DNA sequencing.
Full Article


Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading